Quick Answer
Twist Bioscience Corp reported Net Income of -$77.67 million for fiscal year 2025.
Twist Bioscience Corp — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$77.67M +62.8% |
-$208.73M -2.0% |
-$204.62M +6.1% |
-$217.86M -43.2% |
-$152.10M -8.7% |
-$139.93M -30.0% |
| Diluted EPS | -$1.30 +63.9% |
-$3.60 +0.0% |
-$3.60 +10.9% |
-$4.04 -28.3% |
-$3.15 +11.8% |
-$3.57 |
| Total Assets | $641.86M +4.5% |
$614.32M -20.9% |
$776.40M -19.2% |
$961.38M +36.9% |
$702.10M +76.0% |
$398.88M +113.3% |
| Cash and Equivalents | $183.05M -19.1% |
$226.32M -21.0% |
$286.47M -24.4% |
$378.69M -18.7% |
$465.83M +397.3% |
$93.67M +100.4% |
| Long-Term Debt | — | — | — | — | — | $1.40M -68.1% |
| Stockholders Equity | $472.96M +0.1% |
$472.69M -24.2% |
$623.43M -21.0% |
$789.38M +35.9% |
$580.82M +72.7% |
$336.26M +121.1% |
| R&D Expense | $80.28M -11.6% |
$90.85M -15.0% |
$106.89M -11.1% |
$120.31M +74.2% |
$69.07M +60.6% |
$43.01M +20.5% |
| Operating Income | -$136.26M +38.3% |
-$220.83M -1.7% |
-$217.16M +7.5% |
-$234.78M -53.7% |
-$152.73M -9.0% |
-$140.08M -28.7% |
| Shares Outstanding | 60.63M +3.0% |
58.88M +2.3% |
57.56M +1.8% |
56.52M +14.2% |
49.50M +9.8% |
45.08M +37.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | December 31, 2025 | -$30.51M | +3.4% | -249.6% |
| Diluted EPS | December 31, 2025 | -$0.50 | +5.7% | -251.5% |
| Total Assets | December 31, 2025 | $638.09M | +4.8% | -0.6% |
| Cash and Equivalents | December 31, 2025 | $148.59M | -32.9% | -18.8% |
| Long-Term Debt | December 31, 2020 | $625.0K | -83.0% | -55.5% |
| Stockholders Equity | December 31, 2025 | $456.10M | +0.0% | -3.6% |
| R&D Expense | December 31, 2025 | $17.13M | -19.6% | -5.1% |
| Operating Income | December 31, 2025 | -$32.90M | +5.0% | -9.2% |
| Shares Outstanding | December 31, 2025 | 61.27M | +2.8% | +1.1% |
- Twist Bioscience Corp reported Net Income of -$77.67 million for fiscal year 2025.
- Twist Bioscience Corp showed an increase of +62.8% in Net Income compared to the prior fiscal year.
- Twist Bioscience Corp reported Diluted EPS of $1.30 per share (loss) for fiscal year 2025.
- Twist Bioscience Corp showed an increase of +63.9% in Diluted EPS compared to the prior fiscal year.
- Twist Bioscience Corp reported Total Assets of $641.86 million for fiscal year 2025.
- Twist Bioscience Corp showed an increase of +4.5% in Total Assets compared to the prior fiscal year.
- Twist Bioscience Corp reported Cash and Equivalents of $183.05 million for fiscal year 2025.
- Twist Bioscience Corp showed a decrease of -19.1% in Cash and Equivalents compared to the prior fiscal year.
- Twist Bioscience Corp reported Long-Term Debt of $1.40 million for fiscal year 2020.
- Twist Bioscience Corp showed a decrease of -68.1% in Long-Term Debt compared to the prior fiscal year.
- Twist Bioscience Corp reported Stockholders Equity of $472.96 million for fiscal year 2025.
- Twist Bioscience Corp showed an increase of +0.1% in Stockholders Equity compared to the prior fiscal year.
- Twist Bioscience Corp reported R&D Expense of $80.28 million for fiscal year 2025.
- Twist Bioscience Corp showed a decrease of -11.6% in R&D Expense compared to the prior fiscal year.
- Twist Bioscience Corp reported Operating Income of -$136.26 million for fiscal year 2025.
- Twist Bioscience Corp showed an increase of +38.3% in Operating Income compared to the prior fiscal year.
- Twist Bioscience Corp reported Shares Outstanding of 60.63 million shares for fiscal year 2025.
- Twist Bioscience Corp showed an increase of +3.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: